Prediction of immunotherapy efficacy for pulmonary lymphoepithelioma-like carcinoma using baseline routine blood tests and serum tumor markers: a multicenter retrospective study

Xiongwen Yang, Yuanwei Liang, Hao Hu, Yubin Zhou, Huiyin Deng, Jian Huang, Maoli Liang, Zihao Yuan, Longyan Dong, Yi Xiao · 2025

Read Prediction of immunotherapy efficacy for pulmonary lymphoepithelioma-like carcinoma using baseline routine blood tests and serum tumor markers: a multicenter retrospective study by Xiongwen Yang, Yuanwei Liang, Hao Hu, Yubin Zhou, Huiyin Deng, Jian Huang, Maoli Liang, Zihao Yuan, Longyan Dong, Yi Xiao (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12709023.txt.

Description

Xiongwen Yang and nine colleagues build a blood-test score to predict who benefits from immunotherapy for a rare lung cancer. Pulmonary lymphoepithelioma-like carcinoma is linked to Epstein-Barr virus, and the standard PD-L1 test predicts checkpoint inhibitor response poorly. The team analyzed 254 patients treated across six Chinese centers.

Their composite score combines routine blood indices and serum tumor markers, fitted against progression-free survival. High scores meant much shorter survival in both training and validation groups, and the score outperformed PD-L1, which lost significance in adjusted models. Nomograms using the score discriminated well. The authors pitch the cheap, universally available test as a practical aid for individualized treatment decisions.

Catalog record

CREATORXiongwen Yang, Yuanwei Liang, Hao Hu, Yubin Zhou, Huiyin Deng, Jian Huang, Maoli Liang, Zihao Yuan, Longyan Dong, Yi Xiao
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE54 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12709023

Browse the full library · About the Tower of Babel